Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model

被引：0
作者：
Ryan Thaliffdeen
Anthony Yu
Karen Rascati
机构：
[1] The University of Texas at Austin,Health Outcomes Division, College of Pharmacy
来源：
Clinical Drug Investigation | 2024年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：209 / 217
页数：8
相关论文
共 50 条
[41]   Comparing the relative cost-effectiveness of oral prophylactic medication vs. botulinum toxin type A (BOTOX®) in the management of migraine headache:: A model evaluating the clinical and economic impact of current treatment options [J].
Goldberg, LD .
VALUE IN HEALTH, 2006, 9 (03) :A80-A80
[42]   Evaluation of the cost-effectiveness of the high-chloride vs. low-chloride crystalloid fluids in hospitalized patients from the us third-party provider perspective [J].
D Makhija ;
S Laplante ;
I Beer ;
C Schermer ;
L Perrault .
Intensive Care Medicine Experimental, 3 (Suppl 1)
[43]   Cost-effectiveness of FDA-approved anti-VEGF treatments, ranibizumab and aflibercept, for diabetic macular edema from a US perspective: analysis of 2-Year Protocol T comparative effectiveness results [J].
Duff, Steve ;
Holekamp, Nancy ;
Rajput, Yamina .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
[44]   Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective [J].
Gerbasi, Margaret E. ;
Stellato, Daniel ;
Ghate, Sameer R. ;
Ndife, Briana ;
Moynahan, Aaron ;
Mishra, Dinesh ;
Gunda, Praveen ;
Koruth, Roy ;
Delea, Thomas E. .
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (12) :1243-1252
[45]   INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC [J].
Schroeder, M. ;
Shah, D. ;
Mursleen, S. ;
Martin, A. ;
Perdrizet, J. ;
Ndirangu, K. ;
Risebrough, N. .
VALUE IN HEALTH, 2018, 21 :S411-S412
[46]   INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC [J].
Mursleen, S. ;
Shah, D. ;
Schroeder, M. ;
Perdrizet, J. ;
Ndirangu, K. ;
Risebrough, N. ;
Martin, A. .
VALUE IN HEALTH, 2018, 21 :S411-S411
[47]   Transcatheter Aortic Valve Implantation With CoreValve For The Treatment Of Severe Aortic Stenosis: Results From A UK Perspective Cost-effectiveness Analysis Using 12 Month Data From The ADVANCE Study [J].
Brecker, Stephen ;
Mealing, Stuart ;
Padhiar, Amie ;
Eaton, James N. ;
Sculpher, Mark ;
Busca, Rachele ;
Bosmans, Johan ;
Gerckens, Ulrich J. ;
Wenaweser, Peter ;
Tamburino, Corrado ;
Bleiziffer, Sabine ;
Piazza, Nicolo ;
Moat, Neil ;
Linke, Axel .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) :B218-B218
[48]   EVALUATION OF THE LONG-TERM COST-EFFECTIVENESS OF REAL TIME CONTINUOUS GLUCOSE MONITORING (RTCGM) VERSUS SELF MONITORING OF BLOOD GLUCOSE (SMBG) ALONE IN TYPE 1 DIABETES FROM THE SWEDISH SOCIETAL PERSPECTIVE [J].
Klinkenbijl, B. ;
Jendle, J. ;
Chaugule, S. ;
Graham, C. .
VALUE IN HEALTH, 2017, 20 (09) :A585-A585
[49]   Cost-Effectiveness of Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration in Germany: Model Analysis From the Perspective of Germany's Statutory Health Insurance System [J].
Neubauer, Aljoscha S. ;
Holz, Frank G. ;
Sauer, Stefan ;
Wasmuth, Timo ;
Hirneiss, Christoph ;
Kampik, Anselm ;
Schrader, Wolfgang .
CLINICAL THERAPEUTICS, 2010, 32 (07) :1343-1356
[50]   Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa [J].
Alshreef, Abualbishr ;
MacQuilkan, Kim ;
Dawkins, Bryony ;
Riddin, Jane ;
Ward, Sue ;
Meads, David ;
Taylor, Matthew ;
Dixon, Simon ;
Culyer, Anthony J. ;
Ruiz, Francis ;
Chalkidou, Kalipso ;
Edoka, Ijeoma .
VALUE IN HEALTH REGIONAL ISSUES, 2019, 19 :65-74
12345